Stockscreener 앱 받기
8.28
0.36%
0.03
시간 외 거래:
8.29
0.010
+0.12%
전일 마감가:
$8.25
열려 있는:
$8.26
하루 거래량:
94,247
Relative Volume:
0.70
시가총액:
$43.80M
수익:
$858.00K
순이익/손실:
$-8.98M
주가수익비율:
-40.21
EPS:
-0.2059
순현금흐름:
$-29.81M
1주 성능:
+0.73%
1개월 성능:
-12.84%
6개월 성능:
+93.17%
1년 성능:
+295.19%
1일 변동 폭
$8.17
$8.36
1주일 범위
$8.00
$8.49
52주 변동 폭
$1.90
$11.49
Rallybio Corp Stock (RLYB) Company Profile
명칭
Rallybio Corp
전화
203- 859-3820
주소
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
8.28 | 43.64M | 858.00K | -8.98M | -29.81M | -0.2059 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-17 | 개시 | H.C. Wainwright | Buy |
| 2023-04-10 | 개시 | Wedbush | Outperform |
| 2022-12-09 | 개시 | JP Morgan | Overweight |
| 2022-02-22 | 개시 | JMP Securities | Mkt Outperform |
| 2021-08-23 | 개시 | Cowen | Outperform |
| 2021-08-23 | 개시 | Evercore ISI | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
모두보기
Rallybio Corp 주식(RLYB)의 최신 뉴스
J&J (NYSE: JNJ) discloses 152,901‑share stake in Rallybio (RLYB) - Stock Titan
RLYB Stock Quote - richtv.io
Rallybio Investors Confront Significant Dilution in Merger as $47.5M Valuation Marks Major Downturn from Earlier Projections - Bitget
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasda - ChartMill
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
RLYB Stock Chart | RALLYBIO CORP (NASDAQ:RLYB) - ChartMill
Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
Setup Watch: Can Rallybio Corporation sustain earnings growth2026 Movers & Precise Entry and Exit Recommendations - baoquankhu1.vn
RLYB Technical Analysis & Stock Price Forecast - Intellectia AI
AI Stocks: Is Rallybio Corporation stock trending bullishWeekly Trade Report & Daily Price Action Insights - baoquankhu1.vn
Rallybio CMO Departs Amid Pending Candid Therapeutics Merger - TipRanks
Rallybio chief medical officer departs as company announces leadership change By Investing.com - Investing.com South Africa
Rallybio chief medical officer departs as company announces leadership change - Investing.com Australia
Rallybio (RLYB) CMO Steven Ryder exits as Candid Therapeutics merger proceeds - Stock Titan
RLYB Should I Buy - Intellectia AI
RALLYBIO CORP (NASDAQ:RLYB) Passes Minervini Trend and High Growth Momentum Filters - ChartMill
Rallybio (NASDAQ:RLYB) Rating Increased to Hold at Wall Street Zen - Defense World
Rallybio to acquire Candid Therapeutics - MSN
Rallybio to acquire Candid Therapeutics in $505M merger deal - MSN
If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan
Here's Why We're Watching Rallybio's (NASDAQ:RLYB) Cash Burn Situation - 富途牛牛
Halper Sadeh LLC is Investigating Whether RLYB, TALK, UNF are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Tiny biotech Rallybio stock surges as $500 million-backed merger fuels investor optimism - msn.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations - marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization - TipRanks
Halper Sadeh LLC is Investigating Whether TALK, JTAI, RLYB are Obtaining Fair Deals for their Shareholders - The Norfolk Daily News
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB - GlobeNewswire Inc.
Rallybio Corporation 2025 10-K: Clinical-Stage Rare Disease Biotech, Pipeline, Partnerships, and Regulatory Overview - Minichart
RLYB Surges on Revenue and Merger Hype Why the Stock Still Dropped - Bitget
Stock Recap: What hedge funds are buying Rallybio CorporationPortfolio Value Summary & Weekly High Conviction Ideas - baoquankhu1.vn
Rallybio (NASDAQ: RLYB) to become Candid after merger, $505.5M financing - Stock Titan
Rallybio 2025 10-K: $0.858M Revenue, $(8.98)M Net Loss - TradingView
Rallybio (NASDAQ: RLYB) plans Candid merger, $505.5M financing and CVR structure - Stock Titan
Rallybio: Net loss improved to $9.0 million in 2025 amid a pending merger, asset sale, and cost reductions - TradingView
Rallybio Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Candid Merging Into Public Market - San Diego Business Journal
RLYB Q4'25 Earnings: EPS estimate is (1.24) USD - TradingView
Retail Surge: Will Rallybio Corporation benefit from current market trendsNew Guidance & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Energy Moves: Can Rallybio Corporation generate free cash flowJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Rallybio Completes Key FNAIT Risk Study, Laying Groundwork for Future Market Moves - TipRanks
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? - PR Newswire
Geopolitics Watch: Whats the profit margin of Rallybio CorporationWeekly Risk Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Brokerages Set Rallybio Corporation (NASDAQ:RLYB) Price Target at $40.00 - Defense World
Rallybio (RLYB) Expected to Announce Earnings on Thursday - MarketBeat
$105M for Starface pimple patches, humanoid robot maker eyes €1B and Rallybio's reverse merger - Axios
Candid Therapeutics to Merge with Rallybio in Reverse Merger - themiddlemarket.com
Rallybio Investor Alert: Merger Investigation Launched - National Today
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation – RLYB - Weekly Voice
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio CorporationRLYB - The AI Journal
Candid lists via Rallybio reverse merger, adds $505m financing - The Pharma Letter
Rallybio Corp (RLYB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):